Skip to main content
. 2017 Oct 10;8(18):3657–3666. doi: 10.7150/jca.20053

Figure 4.

Figure 4

Overall survival (A) and progression-free survival (B) of the DP group (n = 43) and the PF group (n = 3). DP, docetaxel plus cisplatin; OS, overall survival; PF, cisplatin plus 5-FU; PFS, progression-free survival.